8-K: Coherus BioSciences to Divest Ophthalmology Franchise to Sandoz for $170 Million

Coherus BioSciences has agreed to sell its ophthalmology business, including CIMERLI, to Sandoz for $170 million in cash, plus inventory value and adjustments.

Summary

• Coherus BioSciences has entered into an agreement to divest its CIMERLI ophthalmology franchise to Sandoz for $170 million in upfront cash.
• The deal also includes an additional amount for CIMERLI product inventory and is subject to customary working capital adjustments.
• The divestiture includes the CIMERLI biologics license application, sales and field reimbursement teams, product inventory, and access to commercial software.
• Coherus aims to use the proceeds to pay down debt, reduce interest costs, and focus on its core oncology business.
• The transaction is expected to close in the first half of 2024, pending regulatory approvals and customary closing conditions.
• The divestiture will also allow Coherus to reduce headcount and overhead costs.

Sentiment

Score: 7

Explanation: The document is positive overall, highlighting a strategic move to focus on core business and reduce debt. However, there are some negatives such as the loss of a revenue stream and headcount reduction. The sentiment is therefore moderately positive.

Positives

• The divestiture allows Coherus to monetize non-core assets.
• The transaction will enable Coherus to pay down debt and reduce interest costs.
• Coherus can now focus on its core oncology business.
• The sale will lead to a reduction in headcount and overhead costs.
• Coherus will receive $170 million in upfront cash, plus additional payments for inventory.

Negatives

• Coherus is divesting a business that has gained strong market share since 2022.
• The company will lose the revenue stream from the ophthalmology franchise.
• There will be a reduction in headcount as a result of the divestiture.

Risks

• The closing of the transaction is subject to customary closing conditions and regulatory approvals, including the Hart-Scott-Rodino Antitrust Improvements Act.
• There is a risk that Coherus may not be able to close the divestiture at all or without incurring substantial costs and other resources.
• The company faces risks and uncertainties inherent in the clinical drug development process and the regulatory approval process.
• There are risks related to existing and potential collaboration partners and the competitive landscape.

Future Outlook

Coherus plans to focus on its core oncology business, including UDENYCA, LOQTORZI, and its immuno-oncology pipeline. The company expects to reduce debt and interest costs and reduce headcount and overhead costs.

Management Comments

• Denny Lanfear, Chairman and Chief Executive Officer of Coherus, stated that the company believes it is prudent to monetize these non-core assets to pay down debt, reduce interest costs, and focus on its core therapeutic area, oncology.
• Lanfear also noted that the divestiture will allow the company to reduce headcount and overhead costs, enhancing its sustainable and growing oncology business.

Industry Context

This divestiture reflects a strategic shift for Coherus, moving away from ophthalmology to concentrate on its oncology portfolio. This is a common strategy for biopharmaceutical companies to focus on core therapeutic areas and improve financial performance.

Comparison to Industry Standards

• The divestiture of a non-core asset for a significant upfront cash payment is a common strategy in the biopharmaceutical industry to streamline operations and focus on core competencies.
• The $170 million upfront payment, plus inventory and working capital adjustments, is a typical structure for such transactions.
• Comparable transactions in the biopharmaceutical sector often involve similar deal structures, including upfront payments, potential milestone payments, and adjustments for inventory and working capital.
• The focus on oncology is a common trend in the biopharmaceutical industry, given the high unmet need and potential for innovation in this therapeutic area.

Stakeholder Impact

• Shareholders will likely view the divestiture positively due to the focus on core business and debt reduction.
• Employees in the ophthalmology division may be impacted by the divestiture.
• Customers of CIMERLI will transition to Sandoz.
• Creditors will benefit from the debt reduction.

Next Steps

• The transaction is expected to close in the first half of 2024.
• Coherus will use the proceeds to pay down debt and reduce interest costs.
• Coherus will focus on its core oncology business.
• The company will reduce headcount and overhead costs.

Key Dates

Keywords

Coherus BioSciences, Sandoz, CIMERLI, ophthalmology, divestiture, oncology, biologics, ranibizumab, acquisition, biosimilar